Open Payments

Kfh - Antioch

Type
Teaching hospital
Where
Antioch, CA
Medicare CCN
050760
Received
$3,713,564 in 122 records, 2024 ($1,055 general, $3,712,509 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment2$1,055
2024Research payment120$3,712,509

By company

CompanyRecordsAmountYears
PFIZER INC.120$3,712,5092024
Ortho-Clinical Diagnostics, Inc.1$8082024
Siemens Medical Solutions USA, Inc.1$2462024

By nature of payment

NatureRecordsAmount
Research payment120$3,712,509
Debt forgiveness2$1,055

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31PFIZER INC.$75,446Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-12-31PFIZER INC.$1,027Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-12-31Siemens Medical Solutions USA, Inc.$246Debt forgivenessIn-kind items and services2024
2024-12-28PFIZER INC.$5,151Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-12-25PFIZER INC.$3,082Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-12-16PFIZER INC.$10,794Research paymentCash or cash equivalentTUKYSA Drug, OncologyRANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJE2024
2024-12-14PFIZER INC.$10,429Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST2024
2024-12-13PFIZER INC.$1,031,200Research paymentCash or cash equivalentOBSERVATIONAL COHORT STUDY EVALUATING REALWORLD ABRYSVO VACCINE EFFECTIVENESS AND IMPACT AGAINST MEDICALLYATTENDED RSVRE2024
2024-12-13PFIZER INC.$3,583Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-12-05PFIZER INC.$47,945Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-12-04PFIZER INC.$23,496Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-12-04PFIZER INC.$10,771Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-11-26PFIZER INC.$64,864Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-11-22PFIZER INC.$23,125Research paymentCash or cash equivalentA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOC2024
2024-11-22PFIZER INC.$23,125Research paymentCash or cash equivalentA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOC2024
2024-11-22PFIZER INC.$23,125Research paymentCash or cash equivalentA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOC2024
2024-11-22PFIZER INC.$23,125Research paymentCash or cash equivalentA PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOC2024
2024-11-09PFIZER INC.$2,003Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-11-08PFIZER INC.$14,492Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-11-07PFIZER INC.$6,300Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2024
2024-10-29PFIZER INC.$5,550Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-10-24PFIZER INC.$3,500Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-10-19PFIZER INC.$17,043Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-10-18PFIZER INC.$1,243Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-10-05PFIZER INC.$2,308Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-10-03PFIZER INC.$8,720Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-10-02PFIZER INC.$8,965Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-09-28PFIZER INC.$20,291Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-09-27PFIZER INC.$947Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-09-18PFIZER INC.$4,720Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-09-13PFIZER INC.$27,000Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-09-12PFIZER INC.$14,119Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W2024
2024-09-11PFIZER INC.$3,747Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-09-10PFIZER INC.$3,796Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-09-10PFIZER INC.$1,272Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-09-04PFIZER INC.$65,592Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-08-29PFIZER INC.$32,037Research paymentIn-kind items and servicesTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-08-27PFIZER INC.$17,892Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-08-24PFIZER INC.$7,947Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-08-24PFIZER INC.$2,060Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST2024
2024-08-21PFIZER INC.$10,000Research paymentCash or cash equivalentTUKYSA Drug, OncologyTHE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CA2024
2024-08-16PFIZER INC.$12,586Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-08-16PFIZER INC.$884Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-08-08PFIZER INC.$618,066Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA POSTMARKETING SAFETY STUDY TO EVALUATE THE SAFETY OF RESPIRATORY SYNCYTIAL VIRUS VACCINE ABRYSVO EXPOSURE DURING PREGN2024
2024-08-07PFIZER INC.$8,965Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-08-03PFIZER INC.$3,747Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-08-03PFIZER INC.$2,270Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-07-26PFIZER INC.$1,500Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST2024
2024-07-17PFIZER INC.$6,950Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-07-17PFIZER INC.$517Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-07-13PFIZER INC.$10,150Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-07-11PFIZER INC.$58,184Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-07-11PFIZER INC.$11,484Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-07-11PFIZER INC.$3,964Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-07-10PFIZER INC.$10,514Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-06-29PFIZER INC.$12,413Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-06-29PFIZER INC.$10,644Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-06-26PFIZER INC.$2,400Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-06-25PFIZER INC.$105Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2024
2024-06-20PFIZER INC.$11,765Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-06-20PFIZER INC.$10,304Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-06-19PFIZER INC.$53,395Research paymentIn-kind items and servicesTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-06-17PFIZER INC.$14Research paymentIn-kind items and servicesAN INTERVENTIONAL PHASE 1B RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED MULTICENTER DOSEFINDING STUDY TO EVALUAT2024
2024-06-13PFIZER INC.$19,125Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-06-08PFIZER INC.$13,662Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-06-08PFIZER INC.$8,119Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2024
2024-06-05PFIZER INC.$7,665Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-06-04PFIZER INC.$50,652Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-06-01PFIZER INC.$8,112Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-05-29PFIZER INC.$123,938Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2024
2024-05-29PFIZER INC.$82,625Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2024
2024-05-29PFIZER INC.$56,961Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2024
2024-05-23PFIZER INC.$19,125Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-05-23PFIZER INC.$19,125Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESA MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VAC2024
2024-05-04PFIZER INC.$2,706Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-05-03PFIZER INC.$1,717Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-05-03PFIZER INC.$925Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2024
2024-04-27PFIZER INC.$24,846Research paymentCash or cash equivalentTALZENNA Drug, ONCOLOGYA PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST2024
2024-04-26PFIZER INC.$32,046Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-04-25PFIZER INC.$32,037Research paymentIn-kind items and servicesTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-04-25PFIZER INC.$6,394Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-04-23Ortho-Clinical Diagnostics, Inc.$808Debt forgivenessCash or cash equivalent2024
2024-04-20PFIZER INC.$4,600Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2024
2024-04-20PFIZER INC.$700Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2024
2024-04-20PFIZER INC.$700Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2024
2024-04-19PFIZER INC.$2,000Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-04-10PFIZER INC.$8,510Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-04-05PFIZER INC.$40,556Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-04-04PFIZER INC.$2,843Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-03-28PFIZER INC.$2,924Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2024
2024-03-26PFIZER INC.$58,819Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-03-23PFIZER INC.$2,960Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-03-13PFIZER INC.$25,375Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-03-13PFIZER INC.$10,290Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-03-12PFIZER INC.$936Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-03-07PFIZER INC.$17,750Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED2024
2024-03-06PFIZER INC.$23,414Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-03-06PFIZER INC.$2,400Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2024
2024-03-05PFIZER INC.$1,593Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-03-05PFIZER INC.$936Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-02-27PFIZER INC.$4,684Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-02-23PFIZER INC.$2,283Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2024
2024-02-21PFIZER INC.$9,420Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-02-16PFIZER INC.$9Research paymentIn-kind items and servicesAN INTERVENTIONAL PHASE 1B RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED MULTICENTER DOSEFINDING STUDY TO EVALUAT2024
2024-02-15PFIZER INC.$126,075Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYDESCRIBE CLINICAL CHARACTERISTICS TREATMENT PATTERNS AND INCIDENCE OF DISEASE RECURRENCE AMONG FEMALE PATIENTS DIAGNOSED2024
2024-02-15PFIZER INC.$16,864Research paymentCash or cash equivalentABRYSVO Biological, VACCINESA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2024
2024-02-09PFIZER INC.$126,075Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYCLINICAL CHARACTERISTICS TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH HRHER2 BREAST CANCER IN THE UNITED STATES2024
2024-02-06PFIZER INC.$16,533Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-02-06PFIZER INC.$14Research paymentIn-kind items and servicesAN INTERVENTIONAL PHASE 1B RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED MULTICENTER DOSEFINDING STUDY TO EVALUAT2024
2024-01-30PFIZER INC.$5,732Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESAN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O2024
2024-01-26PFIZER INC.$17,105Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-01-25PFIZER INC.$1,421Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-01-25PFIZER INC.$1,241Research paymentCash or cash equivalentLITFULO Drug, IMMUNOLOGYA PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE2024
2024-01-18PFIZER INC.$113,870Research paymentCash or cash equivalentTUKYSA Drug, OncologyPHASE 2 RANDOMIZED DOUBLEBLINDED CONTROLLED STUDY OF TUCATINIB2024
2024-01-18PFIZER INC.$11,160Research paymentCash or cash equivalentTUKYSA Drug, OncologyPHASE 2 RANDOMIZED DOUBLEBLINDED CONTROLLED STUDY OF TUCATINIB2024
2024-01-17PFIZER INC.$2,800Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2024
2024-01-17PFIZER INC.$1,750Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2024
2024-01-17PFIZER INC.$1,750Research paymentCash or cash equivalentCOMIRNATY Biological, VACCINESPHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB2024
2024-01-16PFIZER INC.$3,186Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2024
2024-01-11PFIZER INC.$312Research paymentCash or cash equivalentTUKYSA Drug, OncologySTUDY OF TUCATINIB VS PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR PATIENTS WITH ADVANCED OR METASTATIC2024
2024-01-06PFIZER INC.$19,302Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024
2024-01-05PFIZER INC.$1,147Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Contra Costa CountyAntioch city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Antioch, CA, county Contra Costa County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Antioch, CA
County
Contra Costa County, CA
State
California
Population B01003116,4771,165,01239,287,377
Population, 2020 census P1115,2911,165,92739,538,223
Median age B0100238.440.537.9
Under 18 B0100122.8%22.0%22.0%
65 and over B0100114.3%17.1%15.7%
Households B1100137,381414,41713,548,091
Foreign born B0500224.6%26.6%27.0%
Median household income B19013$97,465$127,229$99,122
Median family income B19113$109,115$148,679$113,346
Per capita income B19301$41,008$62,927$49,513
Poverty rate B1700111.4%8.4%12.0%
Unemployment rate B230257.4%6.5%6.6%
Civilian labor force B2302560,709608,62020,068,466
Mean commute (minutes) B0801342.035.328.7
Bachelor's degree or higher B1500323.9%45.2%37.1%
Housing units B2500138,629429,26014,644,735
Owner-occupied B2500363.6%68.0%55.9%
Renters B2500336.4%32.0%44.1%
Median home value B25077$629,700$866,800$734,700
Median gross rent B25064$2,278$2,375$2,036
White, not Hispanic B0300223.4%38.1%33.8%
Black B0300218.2%7.9%5.2%
Hispanic or Latino B0300235.6%27.6%40.2%
Asian B0300213.9%18.6%15.3%
American Indian and Alaska Native B030020.5%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Antioch, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.